AstraZeneca (AZN) to Release Quarterly Earnings on Tuesday

AstraZeneca (NASDAQ:AZN) is set to post its earnings data before the market opens on Tuesday, November 12th. Analysts expect AstraZeneca to post earnings of $1.02 per share for the quarter.

AstraZeneca Stock Performance

NASDAQ AZN traded down $4.80 on Tuesday, reaching $66.63. The stock had a trading volume of 9,673,294 shares, compared to its average volume of 5,050,420. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The stock has a market cap of $206.59 billion, a P/E ratio of 32.11, a price-to-earnings-growth ratio of 1.32 and a beta of 0.47. The business’s 50-day moving average price is $78.87 and its 200 day moving average price is $78.77. AstraZeneca has a 12-month low of $60.47 and a 12-month high of $87.68.

Analyst Ratings Changes

AZN has been the topic of several research reports. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Finally, TD Cowen increased their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and an average price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.